Products
Cangrelor is commercially available as a powder for the preparation of an infusion solution (Kengrexal). It was approved in many countries in 2015.
Structure and properties
Cangrelor (C17H25Cl2F3N5O12P3S2, Mr = 776.4 g/mol) is an analog of adenosine triphosphate. Unlike other P2Y12 antagonists, it is not a prodrug. It is present in the drug as a tetrasodium salt.
Effects
Cangrelor (ATC B01AC25) has antiplatelet and antithrombotic properties. The effects are due to selective and reversible antagonism at the adenosine diphosphate receptor P2Y12 on platelets. Cangrelor has a rapid onset of action, a short half-life, and therefore can be well controlled.
Indications
To reduce the periprocedural risk of cardiovascular thrombotic events during percutaneous coronary intervention in adults with coronary artery disease.
Dosage
According to the SmPC. Cangrelor is administered as an intravenous infusion.
Adverse effects
The most common potential adverse effects include bleeding and dyspnea.
